Skip to main content
AmigoFish

Inside the growing world of biopharma prediction markets

From The Top Line · · 23 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks for an industry where employees, researchers, contractors and others may have access to confidential information that could give them an edge.

In this episode of “The Top Line,” Fierce Biotech’s Will Maddox talks with David Oliwenstein, a partner at Pillsbury Winthrop Shaw Pittman and former SEC enforcement attorney, about how regulators may approach misuse of nonpublic information in prediction markets, why biopharma could face heightened scrutiny and what companies should be doing now to reduce their risk.

To learn more about the topics in this episode:

- Betting on biotech: Prediction markets set sights on clinical trials (https://www.fiercebiotech.com/biotech/betting-biotech-prediction-markets-set-sights-clinical-trials)

See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.

Back to The Top Line · Report a problem